{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:38:16Z","timestamp":1790699896302,"version":"4.1.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"\n Importance<\/jats:title>\n Some individuals are predisposed to cancer based on their substance use history, and others may use substances to manage cancer-related symptoms. Yet the intersection of substance use disorder (SUD) and cancer is understudied. Because SUD may affect and be affected by cancer care, it is important to identify cancer populations with a high prevalence of SUD, with the goal of guiding attention and resources toward groups and settings where interventions may be needed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe the cancer type\u2013specific prevalence of SUD among adult cancer survivors.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This cross-sectional study used data from the annually administered National Survey on Drug Use and Health (NSDUH) for 2015 through 2020 to identify adults with a history of solid tumor cancer. Substance use disorder was defined as meeting at least 1 of 4\n Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition)<\/jats:italic>\n criteria for abuse or at least 3 of 6 criteria for dependence.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Per NSDUH guidelines, we made adjustments to analysis weights by dividing weights provided in the pooled NSDUH data sets by the number of years of combined data (eg, 6 for 2015-2020). The weighted prevalence and corresponding SEs (both expressed as percentages) of active SUD (ie, within the past 12 months) were calculated for respondents with any lifetime history of cancer and, in secondary analyses, respondents diagnosed with cancer within 12 months prior to taking the survey. Data were analyzed from July 2022 to June 2023.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study included data from 6101 adult cancer survivors (56.91% were aged 65 years or older and 61.63% were female). Among lifetime cancer survivors, the prevalence of active SUD was 3.83% (SE, 0.32%). Substance use disorder was most prevalent in survivors of head and neck cancer (including mouth, tongue, lip, throat, and pharyngeal cancers; 9.36% [SE, 2.47%]), esophageal and gastric cancer (9.42% [SE, 5.51%]), cervical cancer (6.24% [SE, 1.41%]), and melanoma (6.20% [SE, 1.34%]). Alcohol use disorder was the most common SUD (2.78% [SE, 0.26%]) overall and in survivors of head and neck cancer, cervical cancer, and melanoma. In survivors of esophageal and gastric cancers, cannabis use disorder was the most prevalent SUD (9.42% [SE, 5.51%]). Among respondents diagnosed with cancer in the past 12 months, the overall prevalence of active SUD was similar to that in the lifetime cancer survivor cohort (3.81% [SE, 0.74%]). However, active SUD prevalence was higher in head and neck (18.73% [SE, 10.56%]) and cervical cancer survivors (15.70% [SE, 5.35%]). The distribution of specific SUDs was different compared with that in the lifetime cancer survivor cohort. For example, in recently diagnosed head and neck cancer survivors, sedative use disorder was the most common SUD (9.81% [SE, 9.17%]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Findings of this study suggest that SUD prevalence is higher among survivors of certain types of cancer; this information could be used to identify cancer survivors who may benefit from integrated cancer and SUD care. Future efforts to understand and address the needs of adult cancer survivors with comorbid SUD should prioritize cancer populations in which SUD prevalence is high.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.5785","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T11:00:53Z","timestamp":1704970853000},"page":"384","source":"Crossref","is-referenced-by-count":25,"title":["Substance Use Disorders Among US Adult Cancer Survivors"],"prefix":"10.1001","volume":"10","author":[{"given":"Katie F.","family":"Jones","sequence":"first","affiliation":[{"name":"New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyomoare L.","family":"Osazuwa-Peters","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Des Marais","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Merlin","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon K.","family":"Check","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"cbr230021r1","doi-asserted-by":"publisher","first-page":"e2013605","DOI":"10.1001\/jamanetworkopen.2020.13605","article-title":"National patterns in prescription opioid use and misuse among cancer survivors in the United States.","volume":"3","author":"Jairam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"cbr230021r2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40737-021-00233-9","article-title":"A comprehensive approach to understanding substance use disorder and recovery: former patients\u2019 experiences and reflections on the recovery process four years after discharge from SUD treatment.","volume":"9","author":"Wangensteen","year":"2022","journal-title":"J Psychosoc Rehabil Ment Health"},{"issue":"3","key":"cbr230021r3","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1016\/j.jpainsymman.2021.05.002","article-title":"Compassion inequities and opioid use disorder: a matched case-control analysis examining inpatient management of cancer-related pain for patients with opioid use disorder.","volume":"62","author":"Singh","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"cbr230021r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size.","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"4","key":"cbr230021r8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cncr.v128.4","article-title":"Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002-2018.","volume":"128","author":"Jiang","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"cbr230021r9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.6004\/jnccn.2019.7341","article-title":"Alcohol use among patients with cancer and survivors in the United States, 2000-2017.","volume":"18","author":"Sanford","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"cbr230021r10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/jnci\/djz233","article-title":"Emergency department visits for opioid overdoses among patients with cancer.","volume":"112","author":"Jairam","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"cbr230021r11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/09540261.2017.1288090","article-title":"The burden of psychosocial morbidity related to cancer: patient and family issues.","volume":"29","author":"Caruso","year":"2017","journal-title":"Int Rev Psychiatry"},{"issue":"8","key":"cbr230021r12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamaoncol.2022.2191","article-title":"Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.","volume":"8","author":"Fitzgerald Jones","year":"2022","journal-title":"JAMA Oncol"},{"issue":"12","key":"cbr230021r13","doi-asserted-by":"publisher","first-page":"e2139968","DOI":"10.1001\/jamanetworkopen.2021.39968","article-title":"Expert panel consensus on management of advanced cancer-related pain in individuals with opioid use disorder.","volume":"4","author":"Merlin","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"cbr230021r14","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1111\/add.v116.10","article-title":"Treatment rates for alcohol use disorders: a systematic review and meta-analysis.","volume":"116","author":"Mekonen","year":"2021","journal-title":"Addiction"},{"key":"cbr230021r15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.genhosppsych.2019.04.016","article-title":"A systematic review of substance use and substance use disorders in patients with cancer.","volume":"60","author":"Yusufov","year":"2019","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"cbr230021r17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.psc.2017.01.005","article-title":"Women and addiction.","volume":"40","author":"Ait-Daoud","year":"2017","journal-title":"Psychiatr Clin North Am"},{"key":"cbr230021r4","unstructured":"Substance Abuse and Mental Health Services Administration. 2021 National Survey on Drug Use and Health (NSDUH). Accessed June 1, 2022. https:\/\/www.samhsa.gov\/data\/release\/2021-national-survey-drug-use-and-health-nsduh-releases"},{"key":"cbr230021r6","unstructured":"Substance Abuse and Mental Health Services Administration. 2015 National Survey on Drug Use and Health Public Use File Codebook. Accessed July 2022. https:\/\/www.datafiles.samhsa.gov\/sites\/default\/files\/field-uploads-protected\/studies\/NSDUH-2015\/NSDUH-2015-datasets\/NSDUH-2015-DS0001\/NSDUH-2015-DS0001-info\/NSDUH-2015-DS0001-info-codebook.pdf"},{"key":"cbr230021r7","unstructured":"Substance Abuse and Mental Health Services Administration. 2020 National Survey on Drug Use and Health Public Use File Codebook. Accessed July 2022. https:\/\/www.datafiles.samhsa.gov\/sites\/default\/files\/field-uploads-protected\/studies\/NSDUH-2020\/NSDUH-2020-datasets\/NSDUH-2020-DS0001\/NSDUH-2020-DS0001-info\/NSDUH-2020-DS0001-info-codebook.pdf"},{"key":"cbr230021r16","unstructured":"Substance Abuse and Mental Health Services Administration. 2021 NSDUH Annual National Report. Accessed June 1, 2022. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2813837\/jamaoncology_jones_2024_br_230021_1710962833.05261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:04:22Z","timestamp":1711019062000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2813837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.5785","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}